Showing 121 - 140 results of 166 for search '"Charles E. Schmidt College of Medicine"', query time: 0.18s Refine Results
  1. 121

    Treatment of Androgenetic Alopecia: Current Guidance and Unmet Needs by Kaiser M, Abdin R, Gaumond SI, Issa NT, Jimenez JJ

    Published 2023-05-01
    “…Phillip Frost Department of Dermatology and Cutaneous Surgery, University of Miami Miller School of Medicine, Miami, FL, USA; 2Charles E. Schmidt College of Medicine, Florida Atlantic University, Boca Raton, FL, USA; 3Forefront Dermatology, Vienna, VA, USA; 4Issa Research and Consulting, LLC, Springfield, VA, USACorrespondence: Joaquin J Jimenez, Phillip Frost Department of Dermatology and Cutaneous Surgery, University of Miami Miller School of Medicine, Miami, FL, USA, Tel +1 305-243-6586, Email j.jimenez@med.miami.eduAbstract: Androgenetic alopecia (AGA) is the most common cause of hair loss in men and women. …”
    Get full text
    Article
  2. 122
  3. 123
  4. 124
  5. 125
  6. 126
  7. 127
  8. 128
  9. 129
  10. 130

    Sarcopenic obesity and cognitive performance by Tolea MI, Chrisphonte S, Galvin JE

    Published 2018-06-01
    “…Magdalena I Tolea,1 Stephanie Chrisphonte,1 James E Galvin1,2 1Charles E. Schmidt College of Medicine, Department of Integrated Medical Sciences, Comprehensive Center for Brain Health, Florida Atlantic University, Boca Raton, FL, USA; 2Christine E. …”
    Get full text
    Article
  11. 131

    Use of immediate-release opioids as supplemental analgesia during management of moderate-to-severe chronic pain with buprenorphine transdermal system by Silverman S, Raffa RB, Cataldo MJ, Kwarcinski M, Ripa SR

    Published 2017-05-01
    “…Sanford Silverman,1,2 Robert B Raffa,3,4 Marc J Cataldo,5 Monica Kwarcinski,5 Steven R Ripa5 1Comprehensive Pain Medicine, Pompano Beach, 2Department of Integrated Medical Sciences, Charles E Schmidt College of Medicine, Florida Atlantic University, Boca Raton, FL, 3Department of Pharmaceutical Sciences, School of Pharmacy, Temple University, Philadelphia, PA, 4Department of Pharmacology and Toxicology, College of Pharmacy, University of Arizona, Tucson, AZ, 5Purdue Pharma LP, Stamford, CT, US Background: The buprenorphine transdermal system (BTDS) is approved in the US for the management of chronic pain. …”
    Get full text
    Article
  12. 132
  13. 133
  14. 134
  15. 135
  16. 136

    24-Month Outcomes of Ahmed ClearPath® Glaucoma Drainage Device for Refractory Glaucoma by Dorairaj S, Checo LA, Wagner IV, Ten Hulzen RD, Ahuja AS

    Published 2022-07-01
    “…Syril Dorairaj,1 Leticia A Checo,1 Isabella V Wagner,1 Richard D Ten Hulzen,1 Abhimanyu S Ahuja2 1Department of Ophthalmology, Mayo Clinic, Jacksonville, FL, USA; 2Charles E. Schmidt College of Medicine, Florida Atlantic University, Boca Raton, FL, USACorrespondence: Syril Dorairaj, Department of Ophthalmology, Mayo Clinic, 4500 San Pablo Road, Jacksonville, FL, USA, Tel +1 904-953-2377, Fax +1 904-953-7040, Email dorairaj.syril@mayo.eduPurpose: To describe the safety and efficacy of the Ahmed ClearPath® (ACP) 250 mm2 glaucoma drainage device (GDD) in the treatment of refractory primary open-angle glaucoma (POAG).Patients and methods: This was a retrospective, noncomparative, single-surgeon, interventional case series of adult patients with medically ± surgically refractory POAG undergoing ACP implantation. …”
    Get full text
    Article
  17. 137
  18. 138
  19. 139
  20. 140